Univariable and multivariable analyses (Cox regression)
| Variable . | Progression . | ||
|---|---|---|---|
| Univariable . | Multivariable 1 (n = 512) . | Multivariable 2 (n = 414) . | |
| Age | |||
| HR | 1.00 | ||
| 95% CI | 0.99-1.01 | ||
| P | .99 | ||
| Male sex | |||
| HR | 1.28 | 1.24 | 1.25 |
| 95% CI | 0.92-1.77 | 0.90-1.72 | 0.87-1.79 |
| P | .14 | .19 | .23 |
| Extranodal disease | |||
| HR | 0.83 | 0.95 | 1.02 |
| 95% CI | 0.56-1.23 | 0.64-1.42 | 0.65-1.58 |
| P | .35 | .81 | .95 |
| Grade 3A or 3 NOS | |||
| HR | 0.91 | ||
| 95% CI | 0.50-1.64 | ||
| P | .75 | ||
| Pretreatment size | |||
| HR | 1.06 | ||
| 95% CI | 0.95-1.17 | ||
| P | .29 | ||
| Stage II disease | |||
| HR | 2.34 | 2.26 | 2.11 |
| 95% CI | 1.66-3.30 | 1.63-3.19 | 1.44-3.10 |
| P | <.0001 | <.0001 | .0001 |
| FLIPI score | |||
| HR | 1.04 | 1.05 | 1.10 |
| 95% CI | 0.80-1.37 | 0.80-1.38 | 0.81-1.50 |
| P | .75 | .71 | .53 |
| BCL2+ (n = 414) | |||
| HR | 1.64 | 1.63 | |
| 95% CI | 1.09-2.46 | 1.07-2.47 | |
| P | .02 | .02 | |
| Variable . | Progression . | ||
|---|---|---|---|
| Univariable . | Multivariable 1 (n = 512) . | Multivariable 2 (n = 414) . | |
| Age | |||
| HR | 1.00 | ||
| 95% CI | 0.99-1.01 | ||
| P | .99 | ||
| Male sex | |||
| HR | 1.28 | 1.24 | 1.25 |
| 95% CI | 0.92-1.77 | 0.90-1.72 | 0.87-1.79 |
| P | .14 | .19 | .23 |
| Extranodal disease | |||
| HR | 0.83 | 0.95 | 1.02 |
| 95% CI | 0.56-1.23 | 0.64-1.42 | 0.65-1.58 |
| P | .35 | .81 | .95 |
| Grade 3A or 3 NOS | |||
| HR | 0.91 | ||
| 95% CI | 0.50-1.64 | ||
| P | .75 | ||
| Pretreatment size | |||
| HR | 1.06 | ||
| 95% CI | 0.95-1.17 | ||
| P | .29 | ||
| Stage II disease | |||
| HR | 2.34 | 2.26 | 2.11 |
| 95% CI | 1.66-3.30 | 1.63-3.19 | 1.44-3.10 |
| P | <.0001 | <.0001 | .0001 |
| FLIPI score | |||
| HR | 1.04 | 1.05 | 1.10 |
| 95% CI | 0.80-1.37 | 0.80-1.38 | 0.81-1.50 |
| P | .75 | .71 | .53 |
| BCL2+ (n = 414) | |||
| HR | 1.64 | 1.63 | |
| 95% CI | 1.09-2.46 | 1.07-2.47 | |
| P | .02 | .02 | |
Analyses of pretreatment patient characteristics associated with progression after primary RT.
NOS, not otherwise specified.